-
Patients with progressive advanced esophagogastric adenocarcinoma treated with docetaxel in addition to active symptom control (ASC) survived 44% longer than those who received ASC alone.
-
In a Phase 2 trial, Ludwig and colleagues present data on 79 patients with relapsed or refractory myeloma who were treated with bendamustine in combination with bortezomib and dexamethasone.
-
In a Phase 3, randomized clinical trial of primary systemic therapy for patients with early, locally advanced breast cancer, the addition of capecitabine to each of six 3-weekly cycles of epirubicin-docetaxel resulted in a 1.64 fold increase in the possibility of primary tumor pathologic complete response.
-
The association between oral contraceptive use and ovarian or breast cancer in BRCA1 or BRCA2 mutation carriers are qualitatively similar to associations reported in the general population.
-
This paper represents the largest collection of cases with central path review and provides better clarity to prognostic factors previously intimated from retrospective work.
-
It is indeed ironic that 16 years after the landmark Burris study, innovations in pancreatic cancer treatment still lack essential quality-of-life data.
-
Calculating 60-day mortality risk by these readily available parameters (ECOG PS and WBC) can be used to identify high-risk patients who may require heightened surveillance after standard or experimental chemotherapy or, alternatively, a reduction in treatment intensity.
-
Hopefully, as multi-institution, randomized trials are developed for second-line treatment of pancreatic cancer, CA19-9 levels will be included both pre- and post-first cycle treatment and responses compared with the established RECIST criteria.
-
In a survey of consecutive myeloma patients from the Mayo Clinic on hypothetical constructs with varying expectations regarding overall survival benefit, toxicity, and financial burden, it was found that the majority of patients would not choose maintenance if toxicity was more than just mild and overall survival benefit was less than 1 year.
-
A previously reported, industry-sponsored phase 3 trial showed improvements in progression-free survival, objective response, and a non-significant trend toward increased overall survival with panitumumab-FOLFIRI vs FOLFIRI alone for second-line wild-type KRAS metastatic colorectal cancer.
